Inhibition of enzymes and secretory transport

Enhancement in Drug Delivery

Volumn , Issue , 2006, Pages 85-109

  Werle, Martin ^a   Bernkop Schnürch, Andreas ^b  

^a ThioMatrix GmbH   (Australia)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350757292     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (212)

1. Swarbrick, J., and J.C. Boylan. 2002. Encyclopedia of pharmaceutical technology, 2nd ed. New York: Marcel Dekker.
2. Bernkop-Schnürch, A. 1997. Strategies for the peroral administration of therapeutic peptides and proteins. Sci Pharm 65:61.
3. Fujii, S., et al. 1985. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J Pharm Pharmacol 37:545.
4. Langguth, P., H.P. Merkle, and G. Amidon. 1994. Oral absorption of peptides-The effect of absorption side and enzyme inhibition on the systemic availability of metkephamid. Pharm Res 11:528.
5. Yamamoto, A., et al. 1994. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 11:1496.
6. Morishita, I., et al. 1992. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharm 78:9.
7. Reseland, J.E., et al. 1996. Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J Nutr 126:634.
8. Otsuki, M., et al. 1987. Effect of synthetic protease inhibitor camostat on pancreatic exocrine function in rats. Pancreas 2:164.
9. Melmed, R.N., A.A. El-Aaser, and S.J. Holt. 1976. Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor. Biochim Biophys Acta 421:280.
10. McGuinness, E.E., D. Hopwood, and K.G. Wormsley. 1982. Further studies of the effects of raw soya flour on the rat pancreas. Scand J Gastroenterol 17:273.
11. Ge, Y.C., and R.G.H. Morgan. 1993. The effect of trypsin inhibitor on the pancreas and small intestine of mice. Br J Nutr 70:333.
12. Raoof, A.A., et al. 2002. Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 17:131.
13. Geary, R.S., et al. 2001. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 293:898.
14. Henry, S.P., et al. 2001. Drug properties of second-generation antisense oligonucleotides: How do they measure up to their predecessors? Curr Opin Investig Drugs 2:1444.
15. Gewirtz, A.M. 1996. Perturbing gene expression with oligodeoxynucleotides: Research and potential therapeutic applications. Mt Sinai J Med 63:372.
16. Haensler, J., and F.C.J. Szoka. 1993. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 4:372.
17. Niedzinski, E.J., et al. 2000. Gastroprotection of DNA with a synthetic cholic acid analog. Lipids 35:721.
18. Huang, L., and S. Li. 1997. Liposomal gene delivery: A complex package. Nat Biotechnol 15:620.
19. Loretz, B., et al. 2006. Oral gene delivery: Strategies to improve stability of pDNA towards intestinal digestion. J Drug Targ in press.
20. Brus, C., et al. 2004. Efficiency of polyethylenimines and polyethylenimine-graft-poly(ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. Eur J Pharm Biopharm 57:427.
21. Glasspool-Malone, J., et al. 2002. DNA transfection of macaque and murine respiratory tissue is greatly enhanced by use of a nuclease inhibitor. J Gene Med 4:323.
22. Ross, G.F., et al. 1998. Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor. Gene Ther 5:1244.
23. Ciftci, K., and R.J. Levy. 2001. Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts. Int J Pharm 218 (1-2):81.
24. Sperinde, J.J., S.J. Choi, and F.C.J. Szoka. 2001. Phage display selection of a peptide DNase II inhibitor that enhances gene delivery. J Gene Med 3:101.
25. Murphy, N.R., S.S. Leinbach, and R.J. Hellwig. 1995. A potent, cost-effective RNase inhibitor. Biotechniques 18:1068.
26. Stryer, L. 1988. Biochemistry, 3rd ed., 226. New York: W.H. Freeman.
27. Okagawa, T., et al. 1994. Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors. Life Sci 55:677.
28. McClellan, J.B.J., and C.W. Garner. 1980. Purification and properties of human intestine alanine aminopeptidase. Biochim Biophys Acta 613:160.
29. Hussain, M.A., et al. 1989. The use of alpha-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption. Pharm Res 6:186.
30. Bernkop-Schnürch, A., and M.K. Marschütz. 1997. Development and in vivo evaluation of systems to protect peptide drugs from aminopeptidase N. Pharm Res 14:181.
31. Bernkop-Schnürch, A., and R. Fragner. 1996. Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration. Pharm Sci 2:361.
32. Hickey, R.J. 1964. Bacitracin, its manufacture and uses. Prog Ind Microbiol 5:93.
33. Langguth, P., et al. 1994. Metabolism and transport of the pentapeptide metkephamid by brushborder membrane vesicles of rat intestine. J Pharm Pharmacol 46:34.
34. Raehs, S.C., et al. 1988. The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharm Res 5:689.
35. Gotoh, S., et al. 1995. Does bacitracin have an absorption-enhancing effect in the intestine? Biol Pharm Bull 18:794.
36. Drapeau, G., et al. 1992. Dissociation of the antimicrobial activity of bacitracin USP from its renovascular effects. Antimicrob Agents Chemother 36:955.
37. Hussain, M.A., et al. 1992. A phosphinic acid dipeptide analogue to stabilize peptide drugs during their intranasal absorption. Pharm Res 9:626.
38. McConnell, R.M., et al. 1991. New pepstatin analogues: Synthesis and pepsin inhibition. J Med Chem 34:2298.
39. Itoh, M., and Y. Matsuo. 1994. Gastric ulcer treatment with intravenous human epidermal growth factor: A double-blind controlled clinical study. J Gastroenterol Hepatol 9:78.
40. Plumpton, C., et al. 1994. Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells-Measurement by two-site enzyme-linked immunosorbent assay. Clin Sci 87:245.
41. McCaffrey, G., and J.C. Jamieson. 1993. Evidence for the role of a cathepsin D-like activity in the release of Gal beta 1-4 GlcNAc alpha 2-6 sialyltransferase for rat and mouse liver in whole-cell systems. Comp Biochem Phys C 104:91.
42. Carmel, R. 1994. In vitro studies of gastric juice in patients with food-cobalamin malabsorption. Dig Dis Sci 39 (12):2516.
43. Walker, B., et al. 1993. Peptide glyoxals-A novel class of inhibitor for serine and cysteine proteinases. Biochem J 193:321.
44. Kimura, T., et al. 1996. Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. Biol Pharm Bull 19:897.
45. Saffran, M., et al. 1988. Vasopressin: A model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharm Sci 77:33.
46. Ushirogawa, Y. 1992. Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhGCSF) in rats. Int J Pharm 81:133.
47. Scott, M.J., et al. 1987. Ovoinhibitor introns specify functional domains as in the related and linked ovomucoid gene. J Biol Chem 262:5899.
48. Kanamori, T., et al. 1988. Expression and excretion of human pancreatic secretory trypsin inhibitor in lipoprotein-deletion mutant of Escherichia coli. Gene 66:295.
49. Luessen, H.L., et al. 1996. Mucoadhesive polymers in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur J Pharm Sci 4:117.
50. Lindahl, A., et al. 1997. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 14:497.
51. Ikesue, K., P. Kopecková, and J. Kopecek. 1993. Degradation of proteins by guinea pig intestinal enzymes. Int J Pharm 95:171.
52. Bernkop-Schnürch, A., C. Paikl, and C. Valenta. 1997. Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm Res 14:917.
53. Sanderink, G.-J., Y. Artur, and G. Siest. 1988. Human aminopeptidase: A review of the literature. J Clin Chem Clin Biochem 26:795.
54. Garner, C.W.J., and F.J. Behal. 1974. Human liver aminopeptidase. Role of metal ions in mechanism of action. Biochemistry 13:3227.
55. Sangadala, S., et al. 1994. A mixture of Manduca sexta aminopeptidase and phosphatase enhances Bacillus thuringiensis insecticidal CryIA(c) toxin binding and 86Rb(+)-K+ efflux in vitro. J Biol Chem 269:10088.
56. Mizuma, T., A. Koyanagi, and S. Awazu. 1997. Intestinal transport and metabolism of analgesic dipeptide, kyotorphin: Rate-limiting factor in intestinal absorption of peptide as drug. Biochim Biophys Acta 1335:111.
57. Lee, V.H.L. 1990. Protease inhibitors and permeation enhancers as approaches to modify peptide absorption. J Control Release 13:213.
58. Luessen, H.L., et al. 1995. Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res 12:1293.
59. Bernkop-Schnürch, A., and N.C. Göckel. 1997. Development and analysis of a polymer protecting from luminal enzymatic degradation caused by a-chymotrypsin. Drug Dev Ind Pharm 23:733.
60. Lehr, C.-M. 1994. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit Rev Ther Drug 11:119.
61. Junginger, H.E. 1990. Bioadhesive polymer systems for peptide delivery. Acta Pharm Technol 36:110.
62. Luessen, H.L., et al. 1996. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 13:1668.
63. Brochard, G., et al. 1996. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III. Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release 39:131.
64. Bernkop-Schnürch, A., and M.E. Krajicek. 1998. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: Synthesis and evaluation of different chitosan-EDTA conjugates. J Control Release 50:215.
65. Luessen, H.L., et al. 1996. Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles. Int J Pharm 141:39.
66. Bernkop-Schnürch, A., C.E. Kast, and D. Guggi. 2003. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/GSH systems. J Control Release 93:95.
67. Bernkop-Schnürch, A., and S. Thaler. 2000. Polycarbophil-cysteine conjugates as platforms for oral (poly)peptide delivery systems. J Pharm Sci 89:901.
68. Bernkop-Schnürch, A., G. Walker, and H. Zarti. 2001. Thiolation of polycarbophil enhances its inhibition of intestinal brush border membrane bound aminopeptidase N. J Pharm Sci 90:1907.
69. Valenta, C., et al. 2002. Evaluation of the inhibition effect of thiolated poly(acrylates) on vaginal membrane bound aminopeptidase N and release of the model drug LH-RH. J Pharm Pharmacol 54:603.
70. Spilburg, C.A., et al. 1995. Identification of a species specific regulatory site in human pancreatic cholesterol esterase. Biochemistry 34:15532.
71. Heidrich, J.E., et al. 2004. Inhibition of pancreatic cholesterol esterase reduces cholesterol absorption in the hamster. BMC Pharmacol 4:5.
72. Wadkins, R.M., et al. 2004. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure- activity relationship analysis, and biological activity. Mol Pharmacol 65:1336.
73. Prueksaritanont, T., et al. 1998. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos 26:520.
74. White, R.D., D.L. Earnest, and D.E. Carter. 1983. The effect of intestinal esterase inhibition on the in vivo absorption and toxicity of di-n-butyl phthalate. Food Chem Toxicol 21:99.
75. Bernkop-Schnürch, A., and K. Dundalek. 1996. Novel bioadhesive drug delivery system protecting (poly)peptides from gastric enzymatic degradation. Int J Pharm 138:75.
76. Bernkop-Schnürch, A., I. Bratengeyer, and C. Valenta. 1997. Development and in vitro evaluation of a drug delivery system protecting from trypsinic degradation. Int J Pharm 157:17.
77. Akiyama, Y., et al. 1996. Novel peroral dosage forms with protease inhibitory activities. 2. Design of fast dissolving poly(acrylate) and controlled drug-releasing capsule formulations with trypsin inhibiting properties. Int J Pharm 138:13.
78. Takada, K., et al. 1991. Effect of pH, dietary proteins and trypsin inhibitors on hydrolytic rate of human granulocyte colony-stimulating factor (G-CSF) by rat digestive enzymes. J Pharmacobiodyn 14:363.
79. Asada, H., et al. 1994. Stability of acyl derivatives of insulin in the small intestine: Relative importance of insulin association characteristics in aqueous solution. Pharm Res 11:1115.
80. Yamamoto, A., E. Hayakawa, and V.H.L. Lee. 1990. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: Implications in peptide delivery from nonoral routes. Life Sci 47:2465.
81. Langguth, P., et al. 1997. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release 46:39.
82. Heizmann, J., et al. 1996. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides 17:1083.
83. Friedman, D.L., and G.L. Amidon. 1991. Oral absorption of peptides: Influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm Res 8:93.
84. Krauland, A.H., D. Guggi, and A. Bernkop-Schnürch. 2004. Oral insulin delivery: The potential of thiolated chitosan-insulin tablets on non-diabetic rats. J Control Release 95:547.
85. Lehr, C.M., et al. 1992. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J Pharm Pharmacol 44:402.
86. Geary, R.S., and H.W. Schlameus. 1993. Vancomycin and insulin used as models for oral delivery of peptides. J Control Release 23:65.
87. New, R.R., et al. 1985. Liposomal immunisation against snake venoms. TOXICON 23:215.
88. Aungst, B.J., and N.J. Rogers. 1988. Site dependence of absorption-promoting actions of Laureth-9, sodium salicylate, disodium EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm Res 5:305.
89. Luessen, H.L., et al. 1997. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J Control Release 45:15.
90. Thiebaut, F., et al. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735.
91. Cordon-Cardo, C., et al. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277.
92. Friend, D.R. 2004. Drug delivery to the small intestine. Curr Gastroenterol Rep 6:371.
93. Romiti, N., et al. 2004. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 76:293.
94. Honda, Y., et al. 2004. Effects of grapefruit juice and orange juice components on P-glycoproteinand MRP2-mediated drug efflux. Br J Pharmacol 143:856.
95. Bailey, D.G., and G.K. Dresser. 2004. Natural products and adverse drug interactions. CMAJ 170:1531.
96. Jodoin, J., M. Demeule, and R. Beliveau. 2002. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542:149.
97. Varma, M.V., et al. 2003. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 48:347.
98. Khan, S.I., et al. 2003. Transport of parthenolide across human intestinal cells (Caco-2). Planta Med 69:1009.
99. Walgren, R.A., et al. 2000. Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294:830.
100. Lowes, S., M.E. Cavet and N.L. Simmons. 2003. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 458:49.
101. Potschka, H., S. Baltes, and W. Loscher. 2004. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 58:85.
102. Olson, D.P., et al. 2002. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16:1743.
103. Makhey, V.D., et al. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15:1160.
104. Seral, C., et al. 2003. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 51:1167.
105. Wang, S., et al. 2004. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistanceassociated protein in multidrug resistance. J Med Chem 47:1329.
106. O’Connor, R., et al. 2004. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24:457.
107. Hu, K., and M.E. Morris. 2004. Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci 93:1901.
108. Leu, B.L., and J.D. Huang. 1995. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432.
109. Malingre, M.M., et al. 2001. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol 57:305.
110. Floren, L.C., et al. 2001. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41.
111. Lennernas, H. 2003. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141.
112. Woo, J.S., et al. 2003. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24.
113. Choi, J.S., H.K. Choi, and S.C. Shin. 2004. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 275:165.
114. Kimura, Y., et al. 2002. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 49:322.
115. Bardelmeijer, H.A., et al. 2004. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 22:219.
116. Bardelmeijer, H.A., et al. 2000. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416.
117. van Asperen, J., et al. 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181.
118. Kuppens, I.E., et al. 2005. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 55:72.
119. Verstuyft, C., et al. 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73:51.
120. Hugger, E.D., et al. 2003. Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. J Pharm Sci 92:21.
121. Hugger, E.D., K.L. Audus, and R.T. Borchardt. 2002. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 91:1980.
122. Batrakova, E.V., et al. 1999. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 16:1366.
123. Bromberg, L., and V. Alakhov. 2003. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 88:11.
124. Banerjee, S.K., et al. 2000. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci 67:2011.
125. Jagannath, C., et al. 1999. Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci 64:1733.
126. Dintaman, J.M., and J.A. Silverman. 1999. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550.
127. Bittner, B., et al. 2002. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung 52:684.
128. Rege, B.D., J.P. Kao, and J.E. Polli. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237.
129. Werle, M., and M. Hoffer. 2006. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Rel 111:41.
130. Foger, F., T. Schmitz, and A. Bernkop-Schnürch. 2006. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27:4250.
131. Baluom, M., M. Friedman, and A. Rubinstein. 2001. Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J Control Release 70:139.
132. Stephens, R.H., et al. 2002. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br J Pharmacol 135:2038.
133. Walle, U.K., and T. Walle. 1998. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 26:343.
134. Fromm, M.F. 2000. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69.
135. Fromm, M.F. 2003. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33:6.
136. Kudlicki, W.A., M.M. Winkler, and B.L. Pastoske. 2003. Nuclease inhibitor cocktail. December 16, 2003, USA.
137. Talib, S., and J.E. Hearst. 1983. Initiation of RNA synthesis in vitro by vesicular stomatitis virus:Single internal initiation in the presence of aurintricarboxylic acid and vanadyl ribonucleoside complexes. Nucleic Acids Res 11:7031.
138. Dellundé, S., et al. 2002. A fast and sensitive nucleic acid extraction method for the detection of Cryptosporidium by PCR in environmental water samples. Water Supply 2:95.
139. Blackburn, P., G. Wilson, and S. Moore. 1977. Ribonuclease inhibitor from human placenta:Purification and properties. J Biol Chem 252:5904.
140. Berger, S.L., and C.S. Birkenmeier. 1979. Inhibition of intractable nucleases with ribonucleoside- vanadyl complexes: Isolation of messenger ribonucleic acid from resting lymphocytes. Biochemistry 18:5143.
141. Morishita, M., et al. 1992. Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation. Int J Pharm 78:1.
142. Murakawa, Y., et al. 1996. Gastrointestinal absorption of recombinant human insulin-like growth factor-I in rats. Proc Int Symp Controlled Release Bioact Mater 23:589.
143. Fjellestad-Paulsen, A., et al. 1996. Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. Eur J Clin Pharmacol 50:491.
144. Trenktrog, T., et al. 1996. Enteric coated insulin pellets-development, drug release and in vivo evaluation. Eur J Pharm Sci 4:323.
145. Birk, Y. 1985. The Bowman-Birk inhibitor. Int J Pept Protein Res 25:113.
146. Suenaga, H., et al. 1995. Strong inhibitory effect of sugar biphenylboronic acid complexes on the hydrolytic activity of alpha-chymotrypsin. J Chem Soc 13:1733.
147. Abd El-Hameeda, M.D., and I.W. Kellaway. 1997. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intra-nasal delivery systems. Eur J Pharm Biopharm 44:53.
148. Powers, J. C., et al. 1977. Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. Biochim Biophys Acta 485:156.
149. Parellada, J., and M. Guinea. 1995. Flavonoid inhibitors of trypsin and leucine aminopeptidase:A proposed mathematical model for IC50 estimation. J Nat Prod 58:823.
150. Manjabacas, M.C., et al. 1995. Kinetic analysis of an autocatalytic process coupled to a reversible inhibition: The inhibition of the system trypsinogen-trypsin by p-aminobenzamidine. Biol Chem Hoppe Seyler 376:577.
151. Artursson, P., et al. 1994. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11:1358.
152. Luessen, H.L., et al. 1995. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res 12:1293.
153. Smith, T.K., et al. 1995. Different sites of acivicin binding and inactivation of gamma-glutamyl transpeptidases. Proc Natl Acad Sci USA 92:2360.
154. Diaz-Flores, M., G. Duran-Reyes, and J.J. Hicks. 1994. Arrest of rat embryonic development by the inhibition of gamma-glutamyl transpeptidase. I. Intrauterine administration of L-serine-borate complex. Int J Fertil Menopausal Stud 39:234.
155. McGwire, G.B., and R.A. Skidgel. 1995. Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. J Biol Chem 270:17154.
156. Borloo, M., and I. De Meester. 1994. Dipeptidyl peptidase IV: Development, design, synthesis and biological evaluation of inhibitors. Verh K Acad Geneeskd Belg 56:57.
157. Kenny, A.J., and S. Maroux. 1982. Topology of microvillar membrane hydrolases of kidney and intestine. Physiol Rev 62:91.
158. Auricchio, S., et al. 1978. Dipeptidylaminopeptidase and carboxypeptidase activities of the brush border of rabbit small intestine. Gastroenterology 75:1073.
159. Giannousis, P.P., and P.A. Bartlett. 1987. Phosphorus amino acid analogues as inhibitors of leucine aminopeptidase. J Med Chem 30:1603.
160. Luciani, N., et al. 1998. Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): Insights into its mechanism of action. Biochemistry 37:686.
161. Huang, K., et al. 1997. Alanyl aminopeptidase from human seminal plasma: Purification, characterization, and immunohistochemical localization in the male genital tract. J Biochem (Tokyo) 122:779.
162. Miller, B.C., et al. 1994. Methionine enkephalin is hydrolyzed by aminopeptidase N on CD4+ and CD8+ spleen T cells. Arch Biochem Biophys 311:174.
163. Taki, Y., et al. 1995. Gastrointestinal absorption of peptide drug: Quantitative evaluation of the degradation and permeation of metkephamid in rat small intestine. J Pharm Exp Therapeut 274:373.
164. Kramer, W., et al. 1990. Intestinal uptake of dipeptides and beta-lactam antibiotics. I. The intestinal uptake system for dipeptides and beta-lactam antibiotics is not part of a brush border membrane peptidase. Biochim Biophys Acta 1030:41.
165. Inoue, T., et al. 1994. Bestatin, a potent aminopeptidase-N inhibitor, inhibits in vitro decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 79:171.
166. Hedeager-Sorensen, S., and A.J. Kenny. 1985. Proteins of the kidney microvillar membrane. Purification and properties of carboxypeptidase P from pig kidneys. Biochem J 229:251.
167. Bunnett, N.W., et al. 1988. Isolation of endopeptidase-24.11 (EC 3.4.24.11, “enkephalinase”) from the pig stomach. Hydrolysis of substance P, gastrin-releasing peptide 10, [Leu5] enkephalin, and [Met5] enkephalin. Gastroenterology 95:952.
168. Ryan, J.W. 1988. Angiotensin-converting enzyme, dipeptidyl carboxypeptidase I, and its inhibitor. Methods Enzymol 163:194.
169. Takada, Y., K. Hiwada, and T. Kokubu. 1981. Isolation and characterization of angiotensin converting enzyme from human kidney. J Biochem 90:1309.
170. Soffer, R.L. 1976. Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annu Rev Biochem 45:73.
171. Bernkop-Schnürch, A., and A. Scerbe-Saiko. 1998. Synthesis and in vitro evaluation of chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery of peptides and proteins. Pharm Res 15:263.
172. Bernkop-Schnürch, A., and I. Apprich. 1997. Synthesis and evaluation of a modified mucoadhesive polymer protecting from a-chymotrypsinic degradation. Int J Pharm 146:247.
173. Bernkop-Schnürch, A., G.H. Schwarz, and M. Kratzel. 1997. Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides. J Control Release 47:113.
174. Rehfeldt, W., K. Resch, and M. Goppelt-Struebe. 1993. Cytosolic phospholipase A2 from human monocytic cells: Characterization of substrate specificity and Ca2+-dependent membrane association. Biochem J 293:255.
175. Akiba, S., et al. 1998. Characterization of acidic Ca2+-independent phospholipase A2 of bovine lung. Comp Biochem Physiol B 120:393.
176. Ciliv, G., and P.T. Oezand. 1972. Human erythrocyte acetylcholinesterase; purification, properties and kinetic behavior. Biochim Biophys Acta 284:136.
177. Larsson Forsell, P.K.A., B.P. Kennedy, and H.E. Claesson. 1999. The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene. Eur J Biochem 262:575.
178. Yang, Y., and M.E. Lowe. 1998. Human pancreatic triglyceride lipase expressed in yeast cells:Purification and characterization. Protein Expr Purif 13:36.
179. Okada, Y., and K. Wakabayashi. 1988. Purification and characterization of esterases D-1 and D-2 from human erythrocytes. Arch Biochem Biophys 263:130.
180. Yang, H.C., A.A. Farooqui, and L.A. Horrocks. 1996. Characterization of plasmalogen-selective phospholipase A2 from bovine brain. Adv Exp Med Biol 416:309.
181. Kawauchi, Y., J. Takasaki, and Y.M. Matsuura. 1994. Preparation and characterization of human rheumatoid arthritic synovial fluid phospholipase A2 produced by recombinant baculovirusinfected insect cells. J Biochem 116:82.
182. Brown, S.S., et al. 1981. The plasma cholinesterase: A new perspective. Adv Clin Chem 22:1.
183. Lombardo, D., O. Guy, and C. Figarella. 1978. Purification and characterization of a carboxyl ester hydrolase from human pancreatic juice. Biochim Biophys Acta 527:142.
184. Primo-Parmo, S.L., H. Lightstone, and B.N. La Du. 1997. Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase. Pharmacogenetics 7:27.
185. Gan, K.N., et al. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19:100.
186. Smolen, A., et al. 1991. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 19:107.
187. Ravazzolo, R., et al. 1988. Characterization, localization, and biosynthesis of acetylcholinesterase in K562 cells. Arch Biochem Biophys 267:245.
188. Saboori, A.M., and D.S. Newcombe. 1990. Human monocyte carboxylesterase. Purification and kinetics. J Biol Chem 265:19792.
189. Lamura, E., et al. 1997. Compartmentalisation and characteristics of a Ca2+-dependent phospholipase A2 in human colon mucosa. Biochem Pharmacol 53:1323.
190. Hojring, N., and O. Svensmark. 1988. Molecular and catalytic properties of a butyrylesterase from human red cells and brain. Arch Biochem Biophys 260:351.
191. Gonzalo, M.C., et al. 1998. Human liver paraoxonase (PON1): Subcellular distribution and characterization. Biochem Mol Toxicol 12:61.
192. Franken, P.A., et al. 1992. Purification and characterization of a mutant human platelet phospholipase A2 expressed in Escherichia coli. Eur J Biochem 203:89.
193. Reiner, E., V. Simeon-Rudolf, and M. Skrinjaric-Spoljar. 1995. Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera. Toxicol Lett 82/83, 447, 1995.
194. Wang, A., et al. 1999. A specific human lysophospholipase: cDNA cloning, tissue distribution and kinetic characterization. Biochim Biophys Acta 1437:157.
195. Tsujita, T., and H. Okuda. 1983. Human liver carboxylesterase. Properties and comparison with human serum carboxylesterase. J Biochem 94:793.
196. Hernandez, A.F., et al. 1993. Characterization of paraoxonase activity in pericardial fluid: Usefulness as a marker of coronary disease. Chem Biol Interact 87:173.
197. Aviram, M., et al. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581.
198. Haagen, L., and A. Brock. 1992. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 30:391.
199. Sihotang, K. 1974. Properties of human erythrocyte acetylcholinesterase. J Biochem 75:939.
200. Hoffmann, G.E., et al. 1992. Characterization of a phospholipase A2 in human serum. Eur J Clin Chem Clin Biochem 30:111.
201. Wigler, P.W. and F.K. Patterson. 1994. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta 1189 (1):1.
202. Kodawara, T., et al. 2002. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res 19 (6):738.
203. Baluom, M., D.I. Friedman, and A. Rubinstein. 1997. Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. Int J Pharm 154:235.
204. Perloff, M.D., et al. 2003. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20:1177.
205. Hollt, V., M. Kouba, M. Dietel, and G. Vogt. 1992. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43:2601.
206. Barancik, M., et al. 1994. Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp Clin Res 20:13.
207. Wandel, C., et al. 2000. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 28:895.
208. Aebi, S., et al. 1999. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol 44:259.
209. Gruol, D.J., and S. Bourgeois. 1994. Expression of the mdr1 P-glycoprotein gene: A mechanism of escape from glucocorticoid-induced apoptosis. Biochem Cell Biol 72:561.
210. Kirk, J., et al. 1994. Reversal of P-glycoprotein-mediated multidrug resistance by pure antioestrogens and novel tamoxifen derivatives. Biochem Pharmacol 48:277.
211. Peck, R.A., et al. 2001. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130.
212. Walker, J., C. Martin, and R. Callaghan. 2004. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40:594.